Lung transplantation has been performed successfully outside Japan since 1983 in patients with end-stage lung disease. More than 9,000 lung transplants have been reported in The Registry of the International Society for Heart and Lung Transplantation. In contrast, a transplant law became effective in Japan only recently, and four universities were designated as official lung transplant centers (Okayama, Osaka, Kyoto and Tohoku Universities).
Introduction
Since the performance of the first successful lung transplantation in 1983 (1), lung transplantation has gained wide spread acceptance as a therapeutic option for patients with various end-stage lung diseases. More than 9,000 lung transplants have been reported in The Registry of the International Society for Heart and Lung Transplantation (2). In contrast, it has been just recently that a transplant law has becomeeffective in Japan; to date only seven lung transplants have been performed.
This article reviews the current status of lung transplantation in the world and in Japan.
History
The first humanlung transplantation was performed by Hardy et al in 1963 (3) . Following that first unsuccessful attempt, approximately 40 patients underwent lung transplantation in medical centers throughout the world during the ensuing 15 years, but none of the recipients survived long term. Manyof these patients were probably moribund at the time of transplantation. Aside from their pretransplant condition, the causes of death included respiratory insufficiency, pneumonia, rejection and airway complications (4). The early results were disappointing but, with the advent of cyclosporine for improved immunosuppression (5), the first successful heart-lung transplantation was reported by the Stan ford group in 1982 (6). Finally, truly long-term survival after single lung transplantation was achieved by Cooper and colleagues in Toronto, the first such operation being performed on November 7, 1983 (1). Three years later, the same group described the first successful series of en bloc double lung transplants (7). Although this procedure did have the definite attraction of preservation of the recipient heart, it was associated with a high incidence of airway complications (8). In 1989 the Washington University group described the technique of bilateral sequential single-lung transplant (9), a procedure that has required only minor modifications during the past decade.
Recipient Selection
Asuccessful transplant program has manyfacets, and selection of suitable recipients is one of them (10). The recipient selection criteria varies somewhat amongcenters depending on the local experience and program emphasis. Recently, "International Guidelines for the Selection of Lung Transplant Candidates" was documented (1 1). In 1997, similar inclusion and exclusion criteria were established in Japan (Table 1) . Following multidisciplinary assessment, a decision is madeto accept or reject the patient as a potential lung transplant recipient by a local committee in official lung transplant centers. Candidates accepted by the committee are evaluated further by a nationwide Central Lung Transplant Evaluation Committee. Then, if accepted, they are listed by the Japan Organ Transplant Network. In the USAand in Europe, the indications for lung transplantation continue to be dominated principally by chronic obstructive pulmonary disease, and cystic fibrosis is the most commonindication for bilateral lung transplantation (2). In From 
Choice of Surgical Technique
Heart-lung transplantation was the first procedure to be successfully performed (6), but it has largely been supplanted by procedures to replace the lung alone. It has been demonstrated that right ventricular function improves immediately after single or bilateral lung transplantation and with long-term follow-up, that improvement is maintained (23) . Heart-lung transplantation is nowused in patients with Eisenmenger's syndrome, and irreparable cardiac defects and in patients with advanced lung disease and concurrent left ventricular dysfunction or extensive coronary artery disease. Patients with restrictive lung disease such as idiopathic pulmonary fibrosis (IPF) have been considered to be ideal candidates for single lung transplantation (SLT) (24) . The native, remaining lung has markedly diminished compliance and increased vascular resistance, so that both ventilation and blood flow are preferentially directed to the transplanted lung. Meyers et al compared SLT and bilateral lung transplantation (BLT)
for IPF and found no benefit of BLTover SLT with this diag-nosis (25) .
Obstructive lung disease, notably emphysema and al-antitrypsin deficiency, have becomethe most commonindication for lung transplantation (2). SLT (26) and BLT (27) have been used with success. BLToffers significant functional advantage in the long term (28) . In SLT, progressive hyperinflation can occur, compressing the allograft and contributing to late deterioration in allograft function (29) . In this setting, surgery to reduce the volumeof the native lung has been reported to improve lung function (30) . Lung volume reduction surgery (LVRS) achieves satisfactory improvement of disabling symptoms early after operation while avoiding immunosuppression and transplant-specific complications (31) (32) (33) . LVRS as a bridge to lung transplantation has been successfully performed (34) .
For infectious lung diseases, such as cystic fibrosis and bronchiectasis, BLT has been exclusively used. Although these patients usually growpseudomonas aeruginosa in their respiratory tract preoperatively, the risk of postoperative infection in these patients is no greater than that in other patient popula-
For patients with pulmonary hypertension, SLT and BLT have been successfully performed (36, 37) . When SLT is performed, high vascular resistance in the native lung requires the allograft to handle nearly the entire cardiac output, potentially causing exaggerated pulmonary edema due to reperfusion and poor allograft function during the immediate postoperative period. However, a recent study of patients with pulmonary hypertension at the University of Pittsburgh found no difference in perioperative oxygenation, the duration of mechanical ventilatory support, or actuarial survival between SLTand BLT (38) . Significant advances in long-term vasodilator therapy (39) have recently shownencouraging results in patients with primary pulmonary hypertension (PPH). Potential candidates for lung transplant with a diagnosis of PPH should be evaluated by a center with experience in vasodilator therapy.
Postoperative Care and Immunosuppression
Most patients are extubated within 24 to 48 hours of transplantation after standard ventilatory support. However,early severe graft dysfunction, as manifested by hypoxia and pulmonary hypertension, occurs in 10% to 20% of lung transplant recipients. A numberof strategies have been developed in an attempt to reduce early allograft dysfunction, for example, use of oxygen-derived radical scavengers (40) , pentoxifylline (4 1 ), and prostaglandin El (42) . Inhaled nitric oxide improves oxygenation and decreases pulmonary artery pressure without systemic circulatory effects and has been widely used (43) . Most clinical lung transplant programs rely on triple-agent immunosuppressionregimens consisting of cyclosporine, azathioprine, and corticosteroids. Somecenters also use antilymphocyte-antibody preparations during the induction phase, but there is no convincing evidence that this approach diminishes the incidence of acute or chronic rejection (44) . A Pittsburgh group has conducted a randomized prospective trial to compare tacrolimus and cyclosporine after lung transplantation (45 The use of radiographic, clinical and physiologic criteria has been insufficient to delineate infection from rejection.
Transbronchial lung biopsy offers a safe and accurate means of diagnosis of acute rejection and has emerged as the procedure of choice (49) .
Airway Complications
In the early days of clinical lung transplantation, dehiscence of the bronchial anastomosis was a frequent source of mortality (4). Based on a series of laboratory investigations by Cooper and colleagues, routine use of omentopexy (50) and avoidance of high-dose perioperative corticosteroids (51) were thought to be key strategies for the first successful humanlung transplantation in 1983. However, recent studies have demonstrated that omentopexy is not essential (52) and early postoperative corticosteroids do not impair airway healing (53) . Donor and recipient peribronchial tissue is used to cover the anastomoses. There seems to be no difference in the airway complication rate between telescoped (54) and end-to-end anastomosis (55) . Direct bronchial revascularization has been reported with low rates of airway complication, however this technique has been used in few centers. Experienced centers have recently reported the incidence to be less than 5% (56).
Bronchiolitis Obliterans Syndrome
Posttransplantation bronchiolitis obliterans syndrome (BOS) is a clinicopathologic syndrome characterized physiologically by airflow limitation and histologically by bronchiolitis obliterans (57) . BOSis considered a manifestation of chronic allograft rejection, and it is the most problematic late complication of lung transplantation. The pathogenesis of bronchiolitis obliterans remains poorly understood. However, the identification of acute rejection as the single mostimportant risk factor substantiates the hypothesis that this disorder is immunologically based (58, 59 plantation with BLThaving a survival advantage (p<0.005).
The 5-year survival was 49% for BLT and 40% for SLT. Survival rates for lung transplantation have improved only moderately over the past 1 0 years despite refinements in surgical technique and postoperative care. These rates lag considerably behind those for heart and liver transplantation, for which 5-year actuarial survival approximates 70%. Experienced centers tend to have better outcomes, hospital death less than 10%and 5-year survival approaching 60% (66) . Among operative survivors, functional results are excellent. The usual patient is returned to normal levels of exercise tolerance without oxygensupplementation within 6 to 8 weeksof transplantation. For patients with obstructive, restrictive or infectious lung diseases, lung transplantation offers significant improvement in pulmonary function and gas exchange (67) . When performed in patients with pulmonary hypertension, both SLT and BLTresult in immediate and sustained normalization of pulmonary vascular resistance and pulmonary arterial pressures. This is accompanied by an immediate increase in cardiac output. (Fig. 3) . The procedure has been performed almost exclusively in patients with cystic fibrosis, though the indications have recently been broadened (69) . Because a limited amount of lung tissue is transplanted, this type of operation is performedunder cardiopulmonary bypass and seems to be best suited for children and small adults. The donors should be larger than the recipient so that the donor lobes fill each hemithorax, thus avoiding persistent pleu- Starnes and colleagues recently reported that pediatric patients receiving LDLLThad less BOSand better pulmonary function than those receiving conventional transplantation of cadaveric lungs (72) . They concluded that LDLLTshould be the preferred method of lung transplantation in children whenever possible.
Living-donor Lobar Lung Transplantation Transplantation of lobes from two healthy living donors is a recently developed technique by Starnes' s group (68). The procedure, living-donor lobar lung transplantation (LDLLT), involves bilateral implantation of the lower lobes from two blood group-compatible living donors

First Successful Living-Donor Lobar Lung
Transplantation in Japan
Our group, from Okayama University, performed the first successful LDLLTon October 28, 1998 (73) . A summary of this case follows; In September 1998, a 24-year-old womanwith primary ciliary dyskinesia began suffering severe respiratory insufficiency and right-sided heart failure after multiple respiratory infections. Chest X-ray showed normal cardiac situs and diffuse bilateral opacification due to generalized bronchiectasis (Fig.  4) . The womanhad bacterial tracheobronchial tract colonization by Pseudomonas aeruginosa and Staphylococcus epidermidis, managed with antibiotics. On October 13, she required mechanical ventilation and a tracheostomy. Right-sided heart failure was observed with a pulmonary artery pressure of 65/35 (47) mmHg.Despite maximal mechanical ventilation, arterial carbon dioxide tension reached 1 50 mmHgon October 28, at which time she underwent bilateral living-donor lobar transplantation with her sister's right lower lobe and her mother's left lower lobe under cardiopulrnonary bypass. Transmission electron microscopy (TEM)of the removed bronchus showedin cilia cross-section that an inner dynein arm deficiency existed. Except for a short lung edema episode requiring nitric oxide inhalation on postoperative day 2, the subsequent course was relatively uneventful. Postoperative immunosuppression involved triple drug therapy of cyclosporine, Date pneumonia (Pseudomonas aeruginosa) in the left lung at 4 months postoperatively; this was successfully managedby antibiotics. Other than this short-term readmission, she has been in good physical condition and returned to a normal, unrestricted lifestyle. The two donors have also recovered fully and returned to their previous lifestyles. One year after transplantation, her chest X-ray demonstrated well-expanded grafts with no detectable dead space (Fig. 5) . Serial changes in the recipient's pulmonary function up to 18 months are depicted in Fig. 6 . Her forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV,) increased gradually, and these improvements were not associated with emphysematous change in transplanted grafts, since FEVj%was stable after 6 months. These were further confirmed by stable functional residual capacity (FRC), residual volume (RV), total lung capacity (TLC), and RV/TLCafter 6 Figure 4 . Preoperative chest X-ray of the patient whoreceived the first living-donor lobar lung transplantation in Japan. Note diffuse bilateral opacity due to generalized bronchiectasis. LungTransplantation months. Serial arterial blood gas analysis showed satisfactory gas exchange. Gradually improving exercise capacity was confirmed objectively by the increase of a 6-minute walking distance.
Changes in FVCof the donors and recipient at 1 year are summarized in Table 3 . Preoperatively, her sister's FVCwas 3,400 ml and her mother's 3,020 ml. Given that the right lower lobe consists of 5 segments and the left lower lobe of 4, total FVCof the 2 grafts was estimated to be 1,530 ml (3,400 mlx5/ 19+3,020 mlx4/19), or 5 1.7% of the recipient's predicted FVC (2,960 ml). One year after transplantation, the decline in FVC was 410 ml (12.1%) forher sister and 440 ml (14.6%) forher mother, making the total FVC decline in the donors 850 ml. The recipient's FVC at 1 year became 2,160 ml, or 73.2% of her predicted FVC.
Current Status of Lung Transplantation in Japan
The history of lung transplantation in Japan has had a long dark period because of the difficulty in accepting the concept of brain death. The transplant law finally became effective in October 1997, and four official lung transplant centers (at Okayama, Osaka, Kyoto and Tohoku Universities) were designated in April 1998.
Receiving lung transplantation in other counties is an option for Japanese patients (74) . A total 6 Japanese patients (including 2 patients from our center) have undergone lung transplantation in the USA. They are all alive and doing well, during a follow-up period to date of 27 to 80 months. This is a very encouraging result. However,this option contains a lot of obstacles including high cost (over $400,000), a long waiting time, language difficulties, the support system, and the ethical issue. It should be noted that donor shortage is also severe in USA.
During the past 7 years, 22 patients were accepted as candidates for lung transplantation in our center (12). Twoof those with primary pulmonary hypertension went to the USAand there received bilateral lung transplant. Twopatients received living-donor lobar lung transplantation in our center. These four recipients are alive and doing well during the follow-up period of 3 to 80 months. In contrast, amongthe 18 patients who have not received lung transplant, 8 patients have died while waiting. The survival of the candidates is quite limited without receiving lung transplantation. Seven lung transplants have been performed in Japan so far (Table 4) . Six of which were performed within the last 7 months. Four were LDLLT.All seven patients are currently alive. Japanese transplant centers should be congratulated for achieving excellent results in their starting phase. Because living-donor lobar lung transplantation requires two healthy donors with a compatible blood type and larger lung than the recipient's, such a methodis not available for most candidates. Therefore, this operation would not be a sufficient solution for the donor shortage. Since the survival of the candidates is quite limited without receiving lung transplantation, living-donor lobar lung transplantation is a realistic option for properly selected candidates. The current transplant law in Japan, the strictest one in the world, may need to be adjusted in the near future to expand the donor pool. 
